Business Wire

Piraeus Bank Group: 9M 2017 Financial Results

Jaa

Key Highlights for the nine months ended 30 September 2017

Improving operating profitability & strengthened financial profile

  • Core banking income, comprising NII and fees, at €558mn in Q3,+5% yoy
  • Operating costs at €288mn in Q3, -4% yoy
  • Cost to income ratio at 49% in Q3 from 55% a year ago
  • Pre provision income at €294mn in Q3, +22% yoy
  • Robust capital position maintained, phased-in CET-1 at 17.0% and fully-loaded at 16.6%

NPEs, NPLs down for 8 th consecutive quarter, best-in-class performance

  • NPE operational target attained seamlessly for 5 quarters
  • NPE stock down to €33.8bn, -€4bn from peak
  • NPE formation at -€0.3bn, NPL formation at -€0.5bn, both pre-write offs
  • NPL stock down to €22.1bn, -€6bn from peak

Increased deposit inflows, decreased eurosystem reliance

  • Deposits in Greece +€0.9bn in Q3
  • Loans to deposits ratio at 109%; 2nd best domestic market level
  • ELA below €6bn in late November; 2nd best domestic market level
  • Successful issue of 5Y €0.5bn covered bond in Oct.17

Significant progress towards successful implementation of “agenda 2020”

  • Piraeus Core Bank €311mn net profit in 9Μ, RoA 1.1%, NIM at 309bps
  • Marginally negative bottom-line on a Group level driven by continuous, intense clean-up
  • New loan generation slightly up for SMEs, aiming at >€1bn new loans in 2018

Management Statement

“Following a period of uncertainty in the beginning of the year, the Greek economy is now back on track. The main indicators in key sectors of the economy are returning to positive territory and sentiment is improving. These developments are gradually feeding into the banking market.

In-line with our commitment to meet the NPEs targets agreed with our supervisory authorities, we outperformed market trends in both NPEs and NPLs reduction. In Q3 NPEs decreased by €0.7bn qoq and by €3.9bn from their peak in Sep.15. Pre write-off NPE formation was negative by -€0.3bn in Q3, the best quarterly performance for Piraeus to-date. NPLs decreased by €0.9bn qoq, down €5.8bn from the Sep.15 peak, reducing drastically the domestic NPL ratio from 40% to 36%. Pre write-off Q3.17 NPL formation was also negative by approximately -€0.5bn in Q3.

The positive trend in domestic customer deposits accelerated in Q3.17, with a quarterly increase of €0.9bn. ELA reliance decreased by €2.5bn in Q3.17 to €7.8bn, reduced further to below €6bn in late November, driven by additional deposit inflows and a more active interbank repo market. Piraeus’ ELA over assets and net loan-to-deposit ratios in Greece are both second best in the market.

Piraeus’ pre-provision income rose by 16% yoy in 9M.17 landing at €844mn, driven by a balanced 5% annual income growth and 5% cost reduction. The core sources of banking revenues, net interest and fee income, recorded a strong increase in Q3 of 5% versus the same period of last year. Our accelerated cost efficiency actions have driven cost-to-income ratio in Greece for 9M.17 to 48% from 54% in 9M.16. As we intensified our efforts to deal with legacy issues, provisions remained elevated, resulting in a marginal 9M.17 bottom-line loss for continuing operations of -€19mn. At the end of Sep.17, the Group’s phased-in and fully-loaded CET-1 capital ratios, both increased qoq, for the 2nd consecutive quarter, to 17.0% and 16.6%, respectively.

The Bank’s transformation journey is progressing with speed and we are focused on the disciplined execution of our strategic plan, “Agenda 2020”, aiming at aggressive balance sheet de-risking and rapid normalisation. Piraeus Core Bank recorded a net profit of €311mn in 9M.17, and a return on assets of 1.1%, highlighting the strength and profitability potential of our business once the Group’s transformation is completed. Piraeus Core Bank delivered a solid set of metrics in 9M.17, including NIM of 309bps and fees over assets of 87bps. “Piraeus Legacy Unit” (“PLU”) continued to contract RWAs by €0.6bn qoq. In the past few months, we have accelerated the pace of our non-core assets disposal program and we are actively contemplating inorganic balance sheet normalisation initiatives, in-line with our de-risking strategy.

The Bank’s reinvigorated management team, including our new Head of PLU, George Georgakopoulos, is working relentlessly towards the implementation of our plan, delivering on commitments and operational targets, while accelerating the clean-up of our balance sheet. We have already started the process for two NPE disposal transactions, one for business and one for consumer loans, of a total NPE on balance sheet amount of c. €2bn. For the full year 2017, we are committed to the accomplishment of our NPE goals, and are targeting a positive bottom-line result.”

Christos Megalou, Chief Executive Officer

Contact information

Piraeus Bank
George Papaioannou
Head of Press Office
gpapai@piraeusbank.gr
+30 210 3288830

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical Trial Ever Conducted in Postpartum Haemorrhage22.2.2018 09:00Tiedote

Ferring Pharmaceuticals and MSD, known as Merck & Co., Inc., Kenilworth, N.J., U.S.A., through its MSD for Mothers initiative, today announced the completion of CHAMPION (Carbetocin Haemorrhage Prevention), a global clinical trial conducted by the Human Reproduction Program (HRP) at the World Health Organization (WHO). CHAMPION is investigating whether Ferring’s proprietary and heat-stable carbetocin could offer a new solution to prevent excessive bleeding after childbirth (postpartum haemorrhage or PPH).2,3 Involving nearly 30,000 women in 10 countries, it is the largest clinical trial ever conducted in PPH.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221006496/en/ Each year, 14 million mothers are affected by PPH.4 As the leading direct cause of maternal mortality, 480,000 mothers died from PPH between 2003-09.1 Even when women survive, PPH can result in the need for serious medical interventions, including surgica

The Nippon Foundation: Project to Map Ocean Floor by 2030 Now Operational22.2.2018 08:00Tiedote

The Nippon Foundation Chairman Yohei Sasakawa announced at a press conference today that The Nippon Foundation – GEBCO Seabed 2030 Project is now operational. The Project will realize Mr. Sasakawa’s vision of mapping the entire ocean floor by 2030. The Nippon Foundation has pledged US$2 million annually, and is calling for additional support from the global ocean community. Mr. Sasakawa noted, “The Nippon Foundation alone cannot achieve the objectives of this ambitious project. We will need the support of diverse stakeholders, including maritime corporations and technical experts. It is crucial that the ocean community comes together to achieve this goal”. He was joined by leading ocean-mapping experts, who emphasized that understanding the bathymetry of the global ocean is imperative for improving maritime navigation, and also for enhancing our ability to predict climate change and monitor marine biodiversity and resources. A comprehensive map of the seafloor will assist global effort

Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis22.2.2018 00:01Tiedote

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation. The study will enroll 360 patients, and the primary endpoint of the study is the mean absolute change from baseline in percent predicted forced expiratory volume in one second (ppFEV1) at week four of treatment. The study is designed to support the submission of a New Drug Application (NDA) in the U.S. using data from the 4-week primary efficacy endpoint together with safety data through 12 weeks of treatment. “Our goal is to bring the best triple combination to patients as rapidly as possible, and this first Phase 3 study of VX-659 in combination with tezacaftor and ivacaftor is a significant step toward that goal,” said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical

Universal Laser Systems® Expands Portfolio of Laser Material Processing Systems with the ULTRA Platform Series21.2.2018 21:00Tiedote

ULTRA platform-based laser systems are designed and ideally suited for precision laser cutting, laser ablation, and laser surface modification in manufacturing, research and development, academic research and prototyping environments. Major features of the series include rapid, high-accuracy laser beam positioning, and the flexibility to be configured with 9.3 and 10.6 µm CO2 lasers and 1.06 µm fiber lasers. All lasers are air-cooled in a range of power from 10 to 150 watts for CO2 and 40 to 50 watts for fiber lasers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005364/en/ The ULTRA 9MW offers MultiWave processing of thin materials. (Photo: Business Wire) The variety of wavelengths and power ranges make the ULTRA platforms highly effective in the areas of organic material modification, including plastic films, industrial fabrics, engineering plastics, laminating adhesives, composite materials, and many others utilized

Luxoft One of Six Companies Collaborating with Amazon Web Services to Accelerate Blockchain Adoption21.2.2018 19:30Tiedote

Luxoft Holding Inc (NYSE:LXFT), a global IT service provider, announces today that it is collaborating with Amazon Web Services (AWS) to enable corporates to adopt blockchain and Distributed Ledger Technologies (DLT). Luxoft is one of six IT and consulting services companies to make its blockchain advisory and development services available to AWS users. “We are very excited to be working with AWS to help users engage with blockchain and DLTs,” said Vasiliy Suvorov, Vice President of Technology Strategy at Luxoft. “Blockchain is about removing data silos, improving trust and operational efficiencies. By using AWS to deploy and integrate DLTs into day-to-day processes, businesses can revolutionize how they operate.” Luxoft helps accelerate the deployment and integration of blockchain and DLT-based projects on AWS and is already working on a number of DLT projects using the cloud. For example, Luxoft is building a healthcare claims processing system for a leading healthcare provider usin

Westinghouse Electric Company to Provide Engineering Support at Vandellós 1 in Partnership with EDF21.2.2018 19:30Tiedote

Westinghouse Electric Company and Electricité de France (EDF), in partnership, announced today that they have been awarded a contract from Empresa Nacional de Residuos Radiactivos (ENRESA), the Spanish agency responsible for radioactive waste management and nuclear plant decommissioning. The agreement covers a four-year engineering support contract for the latency phase of the dismantling and decommissioning project at Vandellós I Nuclear Power Station in Spain and includes the preparation of technical and licensing documentation. “We are extremely pleased that ENRESA has selected Westinghouse and EDF to continue supporting the decommissioning activities at Vandellós I Nuclear Power Station,” said Yves Brachet, Westinghouse vice president, Global Decommissioning, Decontamination, Remediation and Waste Management. “This contract further demonstrates Westinghouse’s global capabilities and expertise in providing innovative decommissioning solutions.” Sylvain Granger, head of EDF's decommi

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme